Cargando…

The Alzheimer's Cell Atlas (TACA): A single‐cell molecular map for translational therapeutics accelerator in Alzheimer's disease

INTRODUCTION: Recent advances in generating massive single‐cell/nucleus transcriptomic data have shown great potential for facilitating the identification of cell type–specific Alzheimer's disease (AD) pathobiology and drug‐target discovery for therapeutic development. METHODS: We developed The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yadi, Xu, Jielin, Hou, Yuan, Bekris, Lynn, Leverenz, James B., Pieper, Andrew A., Cummings, Jeffrey, Cheng, Feixiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558163/ https://www.ncbi.nlm.nih.gov/pubmed/36254161 http://dx.doi.org/10.1002/trc2.12350

Ejemplares similares

AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery
por: Zhou, Yadi, et al.
Publicado: (2021)

Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease
por: Xu, Jielin, et al.
Publicado: (2021)

Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer’s disease
por: Xu, Jielin, et al.
Publicado: (2022)

Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease
por: Fang, Jiansong, et al.
Publicado: (2022)

Alzheimer's disease drug development pipeline: 2023
por: Cummings, Jeffrey, et al.
Publicado: (2023)

Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes
por: Pillai, Jagan A., et al.
Publicado: (2021)

Key inflammatory pathway activations in the MCI stage of Alzheimer’s disease
por: Pillai, Jagan A., et al.
Publicado: (2019)

Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease
por: Pillai, Jagan A., et al.
Publicado: (2023)

Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment
por: Zhou, Yadi, et al.
Publicado: (2021)

Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment
por: Zhou, Yadi, et al.
Publicado: (2021)

Potential role of miRNA-140 in Alzheimer’s disease
por: Akhter, Rumana, et al.
Publicado: (2019)

Tools and algorithms for the construction and analysis of systems: a special issue for TACAS 2020
por: Biere, Armin, et al.
Publicado: (2022)

TNFRSF1B Gene Variants and Related Soluble TNFR2 Levels Impact Resilience in Alzheimer's Disease
por: Pillai, Jagan A., et al.
Publicado: (2021)

Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease
por: Cummings, Jeffrey, et al.
Publicado: (2022)

Niosomes as Biocompatible Scaffolds for the Multivalent Presentation of Tumor-Associated Antigens (TACAs) to the Immune System
por: Fallarini, Silvia, et al.
Publicado: (2022)

Single-cell network biology characterizes cell type gene regulation for drug repurposing and phenotype prediction in Alzheimer’s disease
por: Gupta, Chirag, et al.
Publicado: (2022)

Altered gene expression in excitatory neurons is associated with Alzheimer's disease and its higher incidence in women
por: Garcia, A. Xavier, et al.
Publicado: (2023)

Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer’s disease
por: Pillai, Jagan A., et al.
Publicado: (2020)

Coated Glass Slides TACAS Are Applicable to Heat-Assisted Immunostaining and In Situ Hybridization at the Electron Microscopy Level
por: Matsui, Takahiro, et al.
Publicado: (2015)

Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
por: Ritter, Aaron, et al.
Publicado: (2015)

Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
por: Cummings, Jeffrey
Publicado: (2023)

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia
por: Matthews, Dawn C., et al.
Publicado: (2021)

Integrated multimodal cell atlas of Alzheimer’s disease
por: Gabitto, Mariano I., et al.
Publicado: (2023)

Alzheimer's disease diagnostic criteria: practical applications
por: Cummings, Jeffrey
Publicado: (2012)

New approaches to symptomatic treatments for Alzheimer’s disease
por: Cummings, Jeffrey
Publicado: (2021)

Translating the biology of aging into novel therapeutics for Alzheimer disease
por: Hara, Yuko, et al.
Publicado: (2019)

CD4+ effector T cells accelerate Alzheimer’s disease in mice
por: Machhi, Jatin, et al.
Publicado: (2021)

Globalization of Alzheimer's disease clinical trials
por: Cummings, Jeffrey, et al.
Publicado: (2011)

Alzheimer's drug-development pipeline: 2016
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Correction to: New approaches to symptomatic treatments for Alzheimer’s disease
por: Cummings, Jeffrey
Publicado: (2021)

Aging‐related cell type‐specific pathophysiologic immune responses that exacerbate disease severity in aged COVID‐19 patients
por: Hou, Yuan, et al.
Publicado: (2022)

Translational Research in Alzheimer’s and Prion Diseases
por: Di Fede, Giuseppe, et al.
Publicado: (2018)

Mapping the Alzheimer’s Brain with Connectomics
por: Xie, Teng, et al.
Publicado: (2012)

Who funds Alzheimer's disease drug development?
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Rapamycin Responds to Alzheimer’s Disease: A Potential Translational Therapy
por: Hou, Si-Jia, et al.
Publicado: (2023)

TREM2 deficiency eliminates TREM2(+) inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models
por: Jay, Taylor R., et al.
Publicado: (2015)

An atlas on biomarkers for Alzheimer's disease
por: Martínez-Rivera, Marta
Publicado: (2013)

Longitudinal change in regional brain volumes with exposure to repetitive head impacts
por: Bernick, Charles, et al.
Publicado: (2020)

The “rights” of precision drug development for Alzheimer’s disease
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
por: Cummings, Jeffrey
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hlassuirlq80v260n707svgb1d